The designation “late Lyme disease” is generally reserved for manifestations occurring more than 4 months after disease onset. Skin, nervous system, and joints are most often affected. Canadian pharmacy
Persistent skin inflammation may cause a distinctive plaque-like lesion called acrodermatitis chronica atrophicans. The lesion is most common with B afzelii infection in Europe and has not been documented in humans in the United States.
Viagra professional information
Late neurologic Lyme disease is characterized by a subtle en-cephalopathy affecting predominantly short-term memory and concentration. Psychometric testing may be necessary to objectively document an abnormality. A mild peripheral sensory neuropathy also occurs; elec-tromyographic results are usually abnormal, but nerve conduction velocities may be normal. Examination of spinal fluid usually reveals a low-grade mononuclear pleocytosis, slightly elevated protein level, and anti-B burgdorferi antibodies resulting from intra-thecal antibody synthesis. Canadian pharmacy viagra
Late joint disease is characterized by chronic inflammatory arthritis in one or more large joints, most often the knee. Evidence to date has not proved conclusively whether infection persists in all patients with late Lyme disease; some manifestations may be immunologically mediated. PCR studies have shown B burgdorferi in joint fluid and spinal fluid of untreated persons with late Lyme disease at initial presentation. Studies of chronic Lyme arthritis have shown that PCR may become negative after antibiotic therapy while inflammation persists, particularly in patients who are positive for HLA-DR4 and who are at increased risk of chronic arthritis. The development of chronic arthritis is also associated with strong immunoreactivity against one of the outer-surface proteins of B burgdorferi (OspA). These data suggest that immunologic mechanisms may contribute to persistent inflammation in immunogenetically susceptible individuals. This may also be true in chronic neurologic Lyme disease, but the data are less conclusive.
Most patients with late Lyme disease are strongly seropositive. Rarely, clinical evidence may firmly support the diagnosis of late disease in seronegative patients. In patients in whom late Lyme disease is suspected, a negative serologic response should stimulate a serious search for an alternative diagnosis.
Treatment
All stages of Lyme disease respond to appropriate antibiotic therapy. Our current recommendations are presented in table 2(Lyme disease treatment). Two to 3 weeks of oral therapy is sufficient for early Lyme disease. Intravenous therapy is usually needed in neurologic Lyme disease to achieve satisfactory antibiotic levels in cerebrospinal fluid. Two to 4 weeks is recommended, and most experts favor the longer course of treatment. A possible exception, Bell’s palsy in patients with normal spinal fluid, has been treated successfully with oral agents. Arthritis, whether acute and intermittent or chronic, has been successfully treated with 4 to 8 weeks of oral therapy.
Canadian viagra
The optimal duration of therapy for late Lyme disease has not been established conclusively. To date, the effectiveness of treatment longer than 4 weeks has not been evaluated in a prospective, randomized, blinded study. Some experts currently recommend continuing treatment for an additional 4 weeks for late Lyme disease manifestations that have not completely responded to an initial 4-week regimen. However, continuing treatment until symptoms have resolved is unnecessary, because improvement may occur gradually after completion of antibiotic therapy. Also, since seropositivity may persist for years after successful treatment, follow-up serologic testing is not helpful.
Recent Comments